GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (FRA:BM8) » Definitions » Cyclically Adjusted PS Ratio

Biomarin Pharmaceutical (FRA:BM8) Cyclically Adjusted PS Ratio : 7.66 (As of May. 16, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical Cyclically Adjusted PS Ratio?

As of today (2024-05-16), Biomarin Pharmaceutical's current share price is €73.34. Biomarin Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €9.57. Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio for today is 7.66.

The historical rank and industry rank for Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:BM8' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 7.85   Med: 17.17   Max: 44.11
Current: 7.85

During the past years, Biomarin Pharmaceutical's highest Cyclically Adjusted PS Ratio was 44.11. The lowest was 7.85. And the median was 17.17.

FRA:BM8's Cyclically Adjusted PS Ratio is ranked worse than
59.38% of 512 companies
in the Biotechnology industry
Industry Median: 5.535 vs FRA:BM8: 7.85

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biomarin Pharmaceutical's adjusted revenue per share data for the three months ended in Mar. 2024 was €2.996. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €9.57 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biomarin Pharmaceutical Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Cyclically Adjusted PS Ratio Chart

Biomarin Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.62 12.73 11.16 11.49 9.59

Biomarin Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.41 9.01 8.96 9.59 8.53

Competitive Comparison of Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio falls into.



Biomarin Pharmaceutical Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=73.34/9.57
=7.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomarin Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Biomarin Pharmaceutical's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.996/131.7762*131.7762
=2.996

Current CPI (Mar. 2024) = 131.7762.

Biomarin Pharmaceutical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.964 100.560 1.263
201409 0.860 100.428 1.128
201412 1.259 99.070 1.675
201503 1.190 99.621 1.574
201506 1.389 100.684 1.818
201509 1.155 100.392 1.516
201512 1.298 99.792 1.714
201603 1.316 100.470 1.726
201606 1.643 101.688 2.129
201609 1.487 101.861 1.924
201612 1.652 101.863 2.137
201703 1.644 102.862 2.106
201706 1.620 103.349 2.066
201709 1.601 104.136 2.026
201712 1.725 104.011 2.185
201803 1.719 105.290 2.151
201806 1.804 106.317 2.236
201809 1.891 106.507 2.340
201812 1.737 105.998 2.159
201903 1.989 107.251 2.444
201906 1.917 108.070 2.338
201909 2.252 108.329 2.739
201912 2.278 108.420 2.769
202003 2.428 108.902 2.938
202006 2.110 108.767 2.556
202009 2.048 109.815 2.458
202012 2.044 109.897 2.451
202103 2.214 111.754 2.611
202106 2.246 114.631 2.582
202109 1.896 115.734 2.159
202112 2.169 117.630 2.430
202203 2.420 121.301 2.629
202206 2.694 125.017 2.840
202209 2.750 125.227 2.894
202212 2.728 125.222 2.871
202303 2.866 127.348 2.966
202306 2.818 128.729 2.885
202309 2.849 129.860 2.891
202312 3.144 129.419 3.201
202403 2.996 131.776 2.996

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biomarin Pharmaceutical  (FRA:BM8) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Biomarin Pharmaceutical Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical (FRA:BM8) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (FRA:BM8) Headlines

No Headlines